Header Logo

Connection

Michael Cookson to Dutasteride

Back to Details
This is a "connection" page, showing publications Michael Cookson has written about Dutasteride.
Michael Cookson
Connection Strength
0.018
Dutasteride
  1. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.